Covance has increased global capacity to conduct metabolite identification supporting preclinical development and early human studies. The company’s metabolite identification services now include14 senior scientists located in Madison, WI and Harrogate, UK, and an instrumentation total of five mass spectrometers, six QTrap mass spectrometers and access to nuclear magnetic resonance (NMR) analysis for unequivocal structural identification.

The additions at the Madison facility were designed accommodate increased client demand resulting from the FDA’s recent Guidance for Industry on Safety Testing of Drug Metabolites.

“These additions build upon our track record of excellence in metabolite identification for preclinical development and early human studies conducted at Covance,” said Jon Denissen, vice president of Global DMPK, Covance. “This shows our commitment to provide clients faster results and with the highest level of expertise and quality.”

Sign up today for Contracting & Outsourcing 2009!
www.contractpharma.com/2009conference